Telix的脑瘤成像剂Pixlumi已被接受欧洲监管审查. Telix's brain tumor imaging agent Pixlumi accepted for European regulatory review.

德力克斯制药公司宣布其用于脑瘤成像剂的应用程序,称为Pixlumi已被欧洲监管机构接受,启动了210天的审查. Telix Pharmaceuticals announced its application for a brain tumor imaging agent called Pixlumi has been accepted by European regulators, launching a 210-day review. 该药物使用F-FET帮助医生区分瘤增长和治疗效果,解决目前没有商业版本的护理缺口. The drug uses F-FET to help doctors distinguish between tumor growth and treatment effects, addressing a gap in current care where no commercial version exists. 如果获得批准, 则可以改善质瘤患者的诊断和治疗决策. If approved, it could improve diagnosis and treatment decisions for patients with gliomas.